IMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC): ASSOCIATION OF BIOMARKERS WITH CLINICAL OUTCOMES

被引：0
|
作者：
Choueri, Toni K. [1 ]
Fishman, Mayer N. [2 ]
Escudier, Bernard [3 ]
McDermott, David F. [4 ]
Kluger, Harriet [5 ]
Stadler, Walter M. [6 ]
Perez-Gracia, Jose L. [7 ]
McNeel, Douglas [8 ]
Curti, Brendan [9 ]
Harrison, Michael R. [10 ]
Plimack, Elizabeth R. [11 ]
Appleman, Leonard [12 ]
Fong, Lawrence [13 ]
Drake, Charles G. [14 ]
Young, Tina C. [15 ]
Chasalow, Scott D. [15 ]
Ross-Macdonald, Petra [15 ]
Simon, Jason S. [15 ]
Walker, Dana [15 ]
Sznol, Mario [5 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Inst Gustave Roussy, Villejuif, France
[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[5] Yale Canc Ctr, New Haven, CT USA
[6] Univ Chicago, Med, Chicago, IL 60637 USA
[7] Univ Navarra Clin, Pamplona, Spain
[8] Univ Wisconsin, Dept Med, Madison, WI USA
[9] Providence Portland Med Ctr, Providence Canc Ctr, Portland, OR USA
[10] Duke Univ, Med Ctr, Durham, NC USA
[11] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[12] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[13] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[14] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[15] Bristol Myers Squibb Co, Princeton, NJ USA
来源：
Asia-Pacific Journal of Clinical Oncology | 2015年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
189
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [21] Outcomes of "real world" treatment for metastatic renal cell carcinoma (mRCC).
    Harrison, Michael Roger
    George, Daniel J.
    Walker, Mark S.
    Hudson, Lori L.
    Chen, Connie
    Korytowsky, Beata
    Stepanski, Edward J.
    Abernethy, Amy P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [22] Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and clinical outcomes.
    King, Jennifer
    Hassoun, Rebecca
    Althouse, Sandra K.
    Fausel, Christopher A.
    Schneider, Bryan P.
    Logan, Theodore F.
    Adra, Nabil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [23] Looking for predictive biomarkers for sunitinib in metastatic renal clear cell carcinoma (mRCC)
    Maroto, P.
    Esteban, E.
    Méndez-Vidal, M. J.
    Fernandez-Parra, E. M.
    Leon, L.
    Perez-Valderrama, B.
    Domenech, M.
    Calderero, V.
    Perez-Gracia, J. L.
    Algaba, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S676 - S676
  • [24] Association of body mass index (BMI) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC)
    Goswamy, Rohit Vivek
    Yildirim, Ahmet
    Choi, Yujin
    Wei, Mengting
    Liu, Yuan
    Brown, Jacqueline T.
    Nazha, Bassel
    Martini, Dylan J.
    Hartman, Caitlin
    McClintock, Greta Russler
    Zhuang, Tony
    Kissick, Haydn
    Harris, Wayne Bernard
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [26] Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
    Escudier, Bernard
    Barthelemy, Philippe
    Ravaud, Alain
    Negrier, Sylvie
    Needle, Michael N.
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [27] Optimal sequence strategy with nivolumab and targeted therapy in patients with metastatic renal cell carcinoma (mRCC)
    Logeart, Juliette
    Simonaggio, Audrey
    Elaidi, Reza Thierry
    Hans, Sophie
    Thibault, Constance
    Oudard, Stephane
    Vano, Yann-Alexandre
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] TiNivo - tivozanib combined with nivolumab: Safety and efficacy in patients with metastatic renal cell carcinoma (mRCC)
    Barthelemy, P.
    Escudier, B.
    Ravaud, A.
    Negrier, S.
    Needle, M. N.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 311 - 311
  • [29] Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials
    Reynolds, Nathan
    Wei, Wei
    Maroli, Kimberly
    Bonham, Amanda
    Nizam, Amanda
    Gilligan, Timothy D.
    Wee, Christopher
    Gupta, Shilpa
    Ornstein, Moshe C.
    JOURNAL OF KIDNEY CANCER AND VHL, 2024, 11 (03): : 51 - 58
  • [30] Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma
    Singla, Nirmish
    Nirschl, Thomas R.
    Obradovic, Aleksandar Z.
    Shenderov, Eugene
    Lombardo, Kara
    Liu, Xiaopu
    Pons, Alice
    Zarif, Jelani C.
    Rowe, Steven P.
    Trock, Bruce J.
    Hammers, Hans J.
    Bivalacqua, Trinity J.
    Pierorazio, Phillip M.
    Deutsch, Julie S.
    Lotan, Tamara L.
    Taube, Janis M.
    Ged, Yasser M. A.
    Gorin, Michael A.
    Allaf, Mohamad E.
    Drake, Charles G.
    SCIENTIFIC REPORTS, 2024, 14 (01)
12345